T1	p 121 131	melanoma .
T2	p 140 323	Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter , randomized trials , conducted by the Eastern Cooperative Oncology Group and the Intergroup
T3	p 709 756	patients in E1684 , E1690 , E1694 , and E2696 .
T4	p 837 860	713 patients randomized
T5	p 1776 1817	patients with high-risk resected melanoma
T6	i 87 116	adjuvant high-dose interferon
T7	i 340 381	adjuvant high-dose IFN-alpha 2b therapy .
T8	i 864 901	high-dose IFN-alpha 2b ( HDI ) or Obs
T9	i 1353 1356	HDI
T10	i 1364 1369	Obs .
T11	i 1669 1672	HDI
T12	i 1680 1683	Obs
T13	i 1820 1823	HDI
T14	o 1196 1230	relapse-free survival ( RFS ) -but
T15	o 1235 1263	overall survival ( OS ) -was
T16	o 1449 1452	RFS
T17	o 1457 1459	OS
T18	o 1654 1657	RFS
T19	o 1722 1724	OS
T20	o 1888 1891	RFS
T21	o 1933 1935	OS